Excellance

Excellance Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of next-generation antibody therapeutics targeting G protein-coupled receptors (GPCRs). The company leverages a proprietary platform to overcome the historical challenges of generating high-affinity, functional antibodies against complex GPCR targets. Its lead program, EB-001, is a potent anti-CCR8 monoclonal antibody designed to selectively deplete regulatory T cells within the tumor microenvironment. Excellance's pipeline also includes candidates targeting GPRC5D for multiple myeloma and other undisclosed GPCRs for oncology and inflammatory indications. The firm aims to address significant unmet medical needs by unlocking the therapeutic potential of the GPCR family, which represents one of the most successful classes of drug targets. By integrating advanced antibody engineering with deep GPCR biology expertise, Excellance is positioning itself as a leader in the GPCR-targeted biologics space.